Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Ackland

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Scientific Reports|September 12, 2025
An authoritarianism-compatible text changes British attitudes towards EU immigrationTessa Buchanan, David J Young, James Ackland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringEdwin J Asturias, Jean-Louis Excler, James Ackland, et al.
Clinical and Vaccine Immunology : CVI|January 25, 2013
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adultsPeter Hayes, Jill Gilmour, Andrea von Lieven, et al.
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Human Vaccines|April 22, 2011
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectorsHiroto Hara, Hiroto Hara, Takashi Hironaka, et al.
AIDS Research and Human Retroviruses|December 1, 2009
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersVadakkuppatu Devasenapathi Ramanathan, Makesh Kumar, Jayashri Mahalingam, et al.
The New England Journal of Medicine|February 22, 2018
Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from BirthJulie E Bines, Jarir At Thobari, Cahya Dewi Satria, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Scientific Reports|September 12, 2025
An authoritarianism-compatible text changes British attitudes towards EU immigrationTessa Buchanan, David J Young, James Ackland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringEdwin J Asturias, Jean-Louis Excler, James Ackland, et al.
Clinical and Vaccine Immunology : CVI|January 25, 2013
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adultsPeter Hayes, Jill Gilmour, Andrea von Lieven, et al.
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Human Vaccines|April 22, 2011
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectorsHiroto Hara, Hiroto Hara, Takashi Hironaka, et al.
AIDS Research and Human Retroviruses|December 1, 2009
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersVadakkuppatu Devasenapathi Ramanathan, Makesh Kumar, Jayashri Mahalingam, et al.
The New England Journal of Medicine|February 22, 2018
Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from BirthJulie E Bines, Jarir At Thobari, Cahya Dewi Satria, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Pageof 1